PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Phase 3

Terminated

Conditions: Obesity

Interventions: Drug: CP-945,598 Treatment A
Drug: CP-945,598 Treatment B
Drug: Placebo

First Posted Date: 2006-09-13

Last Posted Date: 2012-11-07

Lead Sponsor: Pfizer

Target Recruit Count: 2536

Registration Number: NCT00375401

Locations: 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Phase 3

Completed

Conditions: Kidney Neoplasms

Interventions: Other: Placebo
Drug: Sunitinib malate

First Posted Date: 2006-09-13

Last Posted Date: 2018-09-21

Lead Sponsor: Pfizer

Target Recruit Count: 674

Registration Number: NCT00375674

Locations: 🇨🇴
Instituto Nacional de Cancerologia - ESE, Bogota, Cundinamarca, Colombia
🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇱
Assaf Harofeh Medical Center, Zerifin, Israel

and more 110 locations

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Sunitinib
Drug: bevacizumab
Drug: paclitaxel

First Posted Date: 2006-09-08

Last Posted Date: 2012-09-10

Lead Sponsor: Pfizer

Target Recruit Count: 488

Registration Number: NCT00373256

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Vaccines, Pneumococcal

Interventions: Biological: 13 valent pneumococcal conjugate vaccine
Biological: 7vPnc pneumococcal conjugate vaccine

First Posted Date: 2006-09-08

Last Posted Date: 2013-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 666

Registration Number: NCT00373958

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Phase 3

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Capecitabine
Drug: Sunitinib malate

First Posted Date: 2006-09-07

Last Posted Date: 2012-06-25

Lead Sponsor: Pfizer

Target Recruit Count: 482

Registration Number: NCT00373113

Locations: 🇬🇧
Pfizer Investigational Site, Somerset, United Kingdom

Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Herceptin
Drug: Sunitinib
Drug: Taxotere

First Posted Date: 2006-09-07

Last Posted Date: 2012-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 26

Registration Number: NCT00372424

Locations: 🇮🇹
Pfizer Investigational Site, Milano, Italy

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Phase 3

Terminated

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: sunitinib malate
Drug: imatinib mesylate

First Posted Date: 2006-09-07

Last Posted Date: 2011-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 69

Registration Number: NCT00372567

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Sunitinib

First Posted Date: 2006-09-07

Last Posted Date: 2011-02-24

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00372775

Locations: 🇪🇸
Pfizer Investigational Site, Valencia, Spain

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: CP-751,871
Drug: exemestane
Drug: Fulvestrant

First Posted Date: 2006-09-07

Last Posted Date: 2015-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 219

Registration Number: NCT00372996

Locations: 🇦🇷
Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina
🇧🇪
UZ Gasthuisberg, Medische Oncologie, Leuven, Belgium
🇦🇷
Centro Oncologico Rosario, Rosario, Santa Fe, Argentina

and more 56 locations

An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

Phase 3

Completed

Conditions: Smoking Cessation

First Posted Date: 2006-09-04

Last Posted Date: 2015-04-22

Lead Sponsor: Pfizer

Target Recruit Count: 334

Registration Number: NCT00371813

Locations: 🇹🇭
Pfizer Investigational Site, Chiang Mai, Thailand

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy